Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early...

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Fabry disease is a genetic disorder that can lead to cardiac complications.
• Enzyme replacement therapy (ERT) with recombinant alpha-galactosidase A is used to treat Fabry disease.
• The long-term effectiveness of ERT in different stages of Fabry cardiomyopathy is not well understood.

Purpose of the Study:

• To evaluate the long-term efficacy of ERT in patients with Fabry cardiomyopathy.
• To determine if the stage of cardiac fibrosis influences the response to ERT.
• To assess the impact of ERT on left ventricular mass, myocardial function, and exercise capacity.

Main Methods:

• A 3-year prospective study of 32 Fabry disease patients receiving ERT.
• Assessment of regional myocardial fibrosis using cardiac MRI.
• Measurement of left ventricular mass by echocardiography.
• Quantification of myocardial function using ultrasonic strain-rate imaging.
• Evaluation of exercise capacity via bicycle stress testing.

Main Results:

• Patients without cardiac fibrosis showed significant reductions in left ventricular mass and improvements in myocardial function and exercise capacity.
• Patients with mild or severe fibrosis had minimal improvement in left ventricular hypertrophy and no improvement in cardiac function or exercise capacity.
• ERT demonstrated significant benefits in patients with Fabry cardiomyopathy prior to the development of significant myocardial fibrosis.

Conclusions:

• ERT with recombinant alpha-galactosidase A is most beneficial when initiated before the onset of myocardial fibrosis in Fabry cardiomyopathy.
• Early intervention is crucial for achieving long-term improvements in cardiac morphology, function, and exercise capacity.
• These findings support timely initiation of ERT to optimize outcomes for patients with Fabry disease.